Neuralink, the neurotechnology company building a generalized input/output platform for the brain, has raised $28.7M in Series B funding. The company's work aims to restore autonomy to those with unmet medical needs and fundamentally transform how humans interact with the world.
Its core technology is an implantable brain-computer interface with ultra-thin, flexible electrode threads placed precisely by a surgical robot, enabling high-bandwidth, bidirectional interaction with neural signals. Neuralink has received multiple FDA Breakthrough Device designations and is conducting clinical trials globally, where participants are exploring how the implant could enhance their daily lives by controlling digital and physical devices, and translating thought directly into speech and text.
